Prior Authorization Delays Vital Transplant Medication
A heart transplant recipient’s experience highlights how prior‑authorization hurdles can jeopardize access to everolimus, a critical immunosuppressive drug. Anthem Blue Cross Blue Shield repeatedly denied coverage, citing the lack of a specific FDA indication for heart transplants, forcing multiple appeals and peer‑to‑peer reviews. Even after approval, the medication was placed in a high‑cost tier and routed through a mail‑order system, creating dangerous delays. The case underscores a systemic disconnect between clinical judgment and insurance protocols, burdening patients with uncertainty and potential health risks.
As Americans Voice Concerns About Health Care and Lose Trust in Federal Institutions, Here’s How CT Has Responded
Americans are increasingly anxious about health‑care access and affordability, with Gallup reporting 61% worried a great deal—up from 51% two years ago. Trust in federal health agencies such as the CDC, FDA and NIH has slipped by up to 7%...
KHL Foundation Launches a Medical Tourism Gene Therapy Program for Older Patients
The KHL Foundation, founded by longevity veterans Ken Scott and Helga Sands, has launched a medical‑tourism program that offers a gene‑therapy cocktail to people over 60. The Rejuvenation Cocktail combines intramuscular follistatin with intranasal klotho and SIRT1, targeting muscle, brain...
Hypnotic-Associated Falls May Signal Circadian Delirium Risk
A recent commentary by Shishida et al. reinterprets hypnotic‑associated falls in hospitalized patients as a potential early indicator of circadian delirium, rather than merely a side effect of sleep‑medication pharmacokinetics. The authors argue that disrupted circadian rhythms may precipitate delirium,...
Pharma M&A Roundup: Gilead Sciences Expands Collaboration with World Health Organization, Johnson & Johnson Enters Collaboration with Department of Health...
Gilead Sciences has renewed a five‑year partnership with the World Health Organization, pledging more than 400,000 vials of AmBisome and $9.2 million to accelerate visceral leishmaniasis elimination, especially in East Africa. The effort builds on a long‑standing collaboration that helped cut...
How Physician Burnout Impacts Modern Health Care
Physician burnout is increasingly visible, even to a child who described hospitals as “mean” to doctors. The article argues that systemic pressures—staffing shortages, electronic medical records, and relentless volume demands—transfer the weight of care onto clinicians. It highlights how burnout...
Scribe Therapeutics Achieves Regulatory Clearance to Initiate First-in-Human Clinical Study of STX-1150 for LDL-C Reduction
Scribe Therapeutics received clearance from Australia’s TGA to start a first‑in‑human Phase 1 study of STX‑1150, an in‑vivo CRISPR‑based therapy that epigenetically silences PCSK9 to lower LDL‑C. The open‑label, single‑ascending‑dose trial will enroll up to 64 high‑risk hypercholesterolemia patients across Australia...
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
Merck has dosed the first patient in the Phase 3 PROCEADE‑CRC‑03 trial of Precem‑TcT, the company’s inaugural anti‑CEACAM5 antibody‑drug conjugate (ADC) featuring an exatecan payload for metastatic colorectal cancer (mCRC). In Phase 1, the ADC achieved a 20.7% confirmed objective response rate...
ASCO 2026: Bayer to Present New Data Across Oncology Portfolio
Bayer announced that it will unveil 16 new oncology abstracts at the ASCO 2026 meeting in Chicago, spanning prostate, breast, lung, renal‑cell, colorectal and salivary‑gland cancers. The headline presentation will feature Phase II head‑to‑head data comparing NUBEQA (darolutamide) with enzalutamide in...
Ontada Integrates Florida Cancer Specialists & Research Institute Data to Enrich Its Data Ecosystem
Ontada, McKesson’s oncology data unit, has integrated Florida Cancer Specialists & Research Institute (FCS) data into its real‑world evidence platform. The addition brings information from more than 530 community oncology providers, including 270,000 extra oral prescriptions covering over 4,000 unique...
Degrader–Antibody Conjugates: Can Targeted Delivery Improve Tolerability?
Degrader‑antibody conjugates (DACs) fuse small‑molecule protein degraders to targeting antibodies, aiming to deliver the degrader selectively to disease‑relevant cells. Early pre‑clinical studies show that DACs can achieve potent target knock‑down while sparing healthy tissue, translating into a markedly better safety...
Stem Cell Therapies for Degenerative Disc Disease and More with BioRestorative’s Lance Alstodt — Episode 256
In the latest Xtalks Life Science Podcast, BioRestorative Therapies CEO Lance Alstodt discussed the company’s stem‑cell‑based programs targeting degenerative disc disease and metabolic disorders. Alstodt highlighted over 25 years of experience in med‑tech, capital raising, and M&A, positioning BioRestorative to...
Q&A: How RWE Is Reshaping Specialty Pharma Market Access
Tommy Bramley, SVP of global consulting at Cencora, says real‑world evidence (RWE) has moved from a post‑approval safety tool to a core component of specialty pharma value dossiers. Payers and providers now expect RWE to inform formulary placement, tiering, and...
System C Sets Out 12-Month AI Roadmap Spanning Emergency, Maternity and Social Care
System C unveiled a 12‑month AI roadmap that will extend its ambient AI capabilities to emergency care this autumn and to maternity services shortly thereafter, building on tools that have already halved documentation time in social‑care settings across 15 English...
How Ossium Health Is Building an Off-the-Shelf Bone Marrow Transplant Model
Ossium Health is developing an off‑the‑shelf bone‑marrow product sourced from deceased organ donors, aiming to eliminate the timing and dose constraints of traditional live‑donor transplants. The company’s first‑in‑human PRESERVE I trial has treated about 25 patients with cryopreserved marrow and...